Moro D, Jacoulet P, Quoix E, Ranfaing E, Brambilla E, Capron F, Lagrange J L, Milleron B, Lebeau B, Ruffie P
Service de pneumologie, Hôpital Michallon, Grenoble, France.
Anticancer Res. 1994 Jan-Feb;14(1B):301-4.
The long-term survivors of SCLC are described in 3 different types of study: analysis of prognostic factors of phase II and III chemotherapy trials (3,4,5,6,7,17,18), epidemiological studies (8) and medical registries of LTS (9,10). A small number of patients with small cell lung cancer achieve long-term survival. Most of these patients have a disease limited to the chest at the time of diagnosis. The major concerns of these LTSs are: the relapse of the SCLC, the occurrence of a second primary tumour and the occurrence of a disease related to tobacco consumption. About 20% of the LTSs die of non-cancer related causes and this exceeds the age adjusted mortality. There is a high risk of relapse in the first 4 years after the diagnosis; this risk decreases later, but relapses may be seen until 7 years. Nearly 8% of LTSs developed a SPTs are alive at 8 years; this indicates that cure is possible in SCLC, however, these patients account for less than 3% of the overall population.
小细胞肺癌(SCLC)的长期生存者在3种不同类型的研究中有描述:II期和III期化疗试验的预后因素分析(3、4、5、6、7、17、18)、流行病学研究(8)以及长期生存者的医学登记(9、10)。少数小细胞肺癌患者实现了长期生存。这些患者中的大多数在诊断时疾病局限于胸部。这些长期生存者的主要担忧是:SCLC复发、第二原发性肿瘤的发生以及与烟草消费相关疾病的发生。约20%的长期生存者死于非癌症相关原因,这超过了年龄调整后的死亡率。诊断后的前4年复发风险很高;这种风险随后降低,但直到7年都可能出现复发。近8%的长期生存者发生了第二原发性肿瘤,8年后仍存活;这表明SCLC有可能治愈,然而,这些患者占总体人群的比例不到3%。